Intravaginally applied oxytocin improves post-menopausal vaginal atrophy

Post Reproductive Health

Volumn 21, Issue 3, 2015, Pages 88-97

  Al Saqi, Shahla H ^a   Uvnäs Moberg, Kerstin ^b,c   Jonasson, Aino F ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^c UNIVERSITY OF SKÖVDE   (Sweden)

Author keywords

Estrogen; Oxytocin; Post menopausal; Vaginal atrophy; Vagitocin

Indexed keywords

ESTRADIOL; FOLLITROPIN; OXYTOCIN; AGENTS USED INTRAVAGINALLY; OXYTOCIC AGENT;

ADULT; ARTICLE; ASSESSMENT OF HUMANS; CLINICAL FEATURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPAREUNIA; DYSURIA; ECHOGRAPHY; ENDOMETRIAL THICKNESS; FEMALE; FEMALE GENITAL TRACT PARAMETERS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MATURATION; MIDDLE AGED; POSTMENOPAUSE; PRURITUS; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; VAGINA ATROPHY; VAGINA PH; VAGINAL ATROPHY SCORE; AGED; ANATOMY AND HISTOLOGY; ATROPHY; CHEMISTRY; COMPLICATION; DRUG EFFECTS; ENDOMETRIUM; INTRAVAGINAL DRUG ADMINISTRATION; OUTCOME ASSESSMENT; PATHOLOGY; PH; SEVERITY OF ILLNESS INDEX; VAGINA; VAGINA SMEAR; VAGINAL DISEASES;

ADMINISTRATION, INTRAVAGINAL; AGED; ATROPHY; DOUBLE-BLIND METHOD; DYSPAREUNIA; ENDOMETRIUM; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MIDDLE AGED; OXYTOCICS; OXYTOCIN; PATIENT OUTCOME ASSESSMENT; POSTMENOPAUSE; SEVERITY OF ILLNESS INDEX; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES; VAGINAL DISEASES; VAGINAL SMEARS;

EID: 84960088972     PISSN: 20533691     EISSN: 20533705     Source Type: Journal    
DOI: 10.1177/2053369115577328     Document Type: Article

References (30)

1. Greendale GA, Lee NP and Arriola ER. The menopause. Lancet 1999; 353: 571–580.
2. Sturdee DW and Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010; 13: 509–522.
3. Nilsson K, Risberg B and Heimer G. The vaginal epithelium in the postmenopause–cytology, histology and pH as methods of assessment. Maturitas 1995; 21: 51–556.
4. Ballagh SA. Vaginal hormone therapy for urogenital and menopausal symptoms. Semin Reprod Med 2005; 23: 126–140.
5. Meisels A. The maturation value. Acta Cytol 1967; 11: 249.
6. Bachmann GA and Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000; 61: 3090–3096.
7. Bergman A, Karram MM and Bhatia NN. Changes in urethral cytology following estrogen administration. Gynecol Obstet Inves 1990; 29: 211–213.
8. Bachmann G, Bouchard C, Hoppe D, et al. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. Menopause 2009; 16: 719–727.
9. Wakavaiachi VM, Girao MJ, Sartori MG, et al. Changes in the lower urinary tract in continent women and in women with stress urinary incontinence, according to menopausal status. Int Urogynecol J Pel 2001; 12: 156–160.
10. Legendre G, Fritel X, Ringa V, et al. [Urinary incontinence and menopause]. Prog Urol 2012; 22: 615–621.
11. Krause M, Wheeler TL 2nd, Snyder TE, et al. Local effects of vaginally administered estrogen therapy: a review. J Pelvic Med Surg 2009; 15: 105–114.
12. Sturdee DW. Hormone replacement therapy preparations. Br Menopause Soc 2000; 6: 34.
13. Sismondi P and Biglia N. Critical review of the article by Colditz et al. on ‘The use of estrogens and progestins and the risk of breast cancer in postmenopausal women’ published in the N.E.J.M. 1995, 332: 1589. Pharmacol Res 1995; 32: 329–330.
14. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, et al. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a populationbased study in southern Europe. Am J Epidemiol 1998; 147: 387–390.
15. Manson JE. Postmenopausal hormone therapy and atherosclerotic disease. Am Heart J 1994; 128: 1337–1343.
16. Lippert TH, Mueck AO, Seeger H, et al. Effects of oxytocin outside pregnancy. Horm Res 2003; 60: 262–271.
17. Gutkowska J, Jankowski M, Mukaddam-Daher S, et al. Oxytocin is a cardiovascular hormone. Brazilian J Med Biol Res 2000; 33: 625–633.
18. Jonasson AF, Edwall L and Uvnas-Moberg K. Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study. Menopause Int 2011; 17: 120–125.
19. Petersson M, Lundeberg T, Sohlstrom A, et al. Oxytocin increases the survival of musculocutaneous flaps. Naunyn Schmiedebergs Arch Pharmacol 1998; 357: 701–714.
20. Lauritzen C. Clinical use of oestrogens and progestogens. Maturitas 1990; 12: 199–214.
21. Cassoni P, Sapino A, Negro F, et al. Oxytocin inhibits proliferation of human breast cancer cell lines. Virchows Arch 1994; 425: 467–472.
22. Shifren JL and Schiff I. Role of hormone therapy in the management of menopause. Obstet Gynecol 2010; 115: 839–855.
23. Beral V, Reeves G, Bull D, et al. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer I 2011; 103: 296–305.
24. Krolik M and Milnerowicz H. The effect of using estrogens in the light of scientific research. Adv Clin Exp Med 2012; 21: 535–543.
25. Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010; 17: 194–203.
26. Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 2014; 18: 1–14.
27. Suckling J, Lethaby A and Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database System Rev 2006; 18: CD001500.
28. Strunecka A, Hynie S and Klenerova V. Role of oxytocin/ oxytocin receptor system in regulation of cell growth and neoplastic processes. Folia Biol 2009; 55: 159–165.
29. Cassoni P, Fulcheri E, Carcangiu ML, et al. Oxytocin receptors in human adenocarcinomas of the endometrium: presence and biological significance. J Pathol 2000; 190: 470–477.
30. Morita T, Shibata K, Kikkawa F, et al. Oxytocin inhibits the progression of human ovarian carcinoma cells in vitro and in vivo. Int J Cancer 2004; 109: 525–532.